Elaine Sullivan

Elaine Sullivan has over 25 years of international experience working in the pharmaceutical industry and was a member of the senior R&D management teams in Eli Lilly and AstraZeneca. She is currently CEO of Keltic Pharma Therapeutics whose focus is to develop new medicines in malaria, respiratory and neurology. Previously she was the co-founder and CEO of Carrick Therapeutics which developed a novel oncology pipeline rapidly transitioning from a preclinical start-up to a clinical stage oncology company. Elaine Sullivan holds a Ph.D. in Molecular Virology from the University of Edinburgh, Scotland.